US Patent

US7795447 — Imidazole compounds for the treatment of neurodegenerative disorders

Composition of Matter · Assigned to Pfizer Inc · Expires 2030-08-18 · 4y remaining

Vulnerability score 23/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of imidazole compounds that inhibit the production of Aβ-peptide, which are useful for treating neurodegenerative disorders such as Alzheimer's disease.

USPTO Abstract

The present invention relates to compounds of the Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

Drugs covered by this patent

Patent Metadata

Patent number
US7795447
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-08-18
Drug substance claim
Yes
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.